Science of DME Newsfeed Archived News
Dexamethasone Intravitreal Implant Gets EU Approval for Treatment of Diabetic Macular Edema
The European Commission has extended marketing authorization for dexamethasone intravitreal implant (Ozurdex) for the treatment of diabetic macular edema in certain patients.
Under the marketing authorization extension, the dexamethasone 0.7 mg intravitreal implant is indicated for adult patients with visual impairment due to diabetic macular edema who are pseudophakic, or who were unable to undergo noncorticosteroid therapy.
The implant is already indicated for the treatment of macular edema following branch retinal vein occlusion and central retinal vein occlusion, as well as for the treatment of noninfectious uveitis, according to the press release. It was approved by the U.S. Food and Drug Administration on June 30.